Emily Rayens1,2, Karen A Norris1, José F Cordero2. 1. Center for Vaccines and Immunology, Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA. 2. Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, Georgia, USA.
Abstract
BACKGROUND: Invasive fungal infections in the United States are chronically underdiagnosed and a lack of coordinated surveillance makes the true burden of disease difficult to determine. The purpose of this analysis was to capture mortality-associated burden of risk conditions and fungal infections. METHODS: We analyzed data from the National Vital Statistics System from 1999 through 2018 to estimate the mortality attributed to risk conditions and related fungal disease. RESULTS: The number of risk conditions associated with fungal disease is steadily rising in the United States, with 1 047 422 diagnoses at time of death in 2018. While fungal disease decreased substantially from 1999 to 2010, primarily due to the control of human immunodeficiency virus (HIV) infection, the number of deaths with fungal diagnosis has increased in the non-HIV cohort, with significant increases in patients with diabetes, cancer, immunosuppressive disorders, or sepsis. CONCLUSIONS: The landscape of individuals at risk for serious fungal diseases is changing, with a continued decline in HIV-associated incidence but increased diagnoses in patients with cancer, sepsis, immunosuppressive disorders, and influenza. Additionally, there is an overall increase in the number of fungal infections in recent years, indicating a failure to control fungal disease mortality in these new immunocompromised cohorts. Improvement in the prevention and management of fungal diseases is needed to control morbidity and mortality in the rising number of immunocompromised and at-risk patients in the United States.
BACKGROUND: Invasive fungal infections in the United States are chronically underdiagnosed and a lack of coordinated surveillance makes the true burden of disease difficult to determine. The purpose of this analysis was to capture mortality-associated burden of risk conditions and fungal infections. METHODS: We analyzed data from the National Vital Statistics System from 1999 through 2018 to estimate the mortality attributed to risk conditions and related fungal disease. RESULTS: The number of risk conditions associated with fungal disease is steadily rising in the United States, with 1 047 422 diagnoses at time of death in 2018. While fungal disease decreased substantially from 1999 to 2010, primarily due to the control of human immunodeficiency virus (HIV) infection, the number of deaths with fungal diagnosis has increased in the non-HIV cohort, with significant increases in patients with diabetes, cancer, immunosuppressive disorders, or sepsis. CONCLUSIONS: The landscape of individuals at risk for serious fungal diseases is changing, with a continued decline in HIV-associated incidence but increased diagnoses in patients with cancer, sepsis, immunosuppressive disorders, and influenza. Additionally, there is an overall increase in the number of fungal infections in recent years, indicating a failure to control fungal disease mortality in these new immunocompromised cohorts. Improvement in the prevention and management of fungal diseases is needed to control morbidity and mortality in the rising number of immunocompromised and at-risk patients in the United States.
Authors: Dimitrios P Kontoyiannis; Kieren A Marr; Benjamin J Park; Barbara D Alexander; Elias J Anaissie; Thomas J Walsh; James Ito; David R Andes; John W Baddley; Janice M Brown; Lisa M Brumble; Alison G Freifeld; Susan Hadley; Loreen A Herwaldt; Carol A Kauffman; Katherine Knapp; G Marshall Lyon; Vicki A Morrison; Genovefa Papanicolaou; Thomas F Patterson; Trish M Perl; Mindy G Schuster; Randall Walker; Kathleen A Wannemuehler; John R Wingard; Tom M Chiller; Peter G Pappas Journal: Clin Infect Dis Date: 2010-04-15 Impact factor: 9.079
Authors: Heather D Green; Rowland J Bright-Thomas; Ken J Mutton; Malcolm Guiver; Andrew M Jones Journal: J Infect Date: 2016-05-14 Impact factor: 6.072
Authors: Marco F Silva; Mariana P Ferriani; Maria T Terreri; Rosa M Pereira; Claudia S Magalhães; Eloisa Bonfá; Lucia M Campos; Eunice M Okuda; Simone Appenzeller; Virgínia P Ferriani; Cássia M Barbosa; Valéria C Ramos; Simone Lotufo; Clovis A Silva Journal: J Rheumatol Date: 2015-12 Impact factor: 4.666
Authors: Cecilia G Carvalhaes; Abby L Klauer; Paul R Rhomberg; Michael A Pfaller; Mariana Castanheira Journal: J Clin Microbiol Date: 2022-03-07 Impact factor: 11.677
Authors: Rebecca A Ward; Nima Aghaeepour; Roby P Bhattacharyya; Clary B Clish; Brice Gaudillière; Nir Hacohen; Michael K Mansour; Philip A Mudd; Shravani Pasupneti; Rachel M Presti; Eugene P Rhee; Pritha Sen; Andrej Spec; Jenny M Tam; Alexandra-Chloé Villani; Ann E Woolley; Joe L Hsu; Jatin M Vyas Journal: Open Forum Infect Dis Date: 2021-09-25 Impact factor: 3.835